Several factors have been identified that may predict super response or refractory response to rituximab among patients with pemphigus.

Please provide your email address to receive an email when new articles are posted on . A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone ...

Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, ...

Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The diagnosis ...

DSG3-CAART is designed to selectively target the cause of mucosal pemphigus vulgaris. The Food and Drug Administration (FDA) has granted Fast Track designation to DSG3-CAART (desmoglein 3 chimeric ...

Pemphigus refers to a group of skin disorders that cause blistering and sores on the skin or mucous membranes of the mouth, nose, throat or genital region. The onset of disease is usually in ...

Presents the case of a pregnant woman with erosions and desquamation with erythematose areas only on the gingiva due to Pemphigus vulgaris. Gingival lesions comprise severe desquamative or erosive ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Rituxan met a primary endpoint and ...

Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not ...

Researchers compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. Pemphigus, an autoimmune disease mediated by B cells and which causes painful ...

Shares of argenx SE ARGX were down 25.1% on Dec 20 after the company announced top-line data from the phase III ADDRESS study, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the pemphigus vulgaris market. The report includes a detailed analysis of the pipeline molecules under ...